このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar Extraction

2026年11月12日 更新者:South Rampart Pharma, Inc.

A Phase 2 Randomized, Double-blind, Placebo-controlled Study Assessing Analgesic Efficacy and Safety of the Novel Non-opioid SRP-001 Compared to Placebo in Patients With Moderate-to-severe Acute Postoperative Pain After Impacted Third Mandibular Molar Extraction

This study tests whether a single oral dose of SRP-001 (2,000 mg), a non-opioid drug, relieves moderate-to-severe pain after surgery to remove impacted third molars (wisdom teeth), compared with placebo. It also evaluates safety and how the body processes the drug.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

This is a single-center, randomized, double-blind, placebo-controlled, parallel-group Phase 2 study evaluating the analgesic efficacy, onset of action, pharmacokinetics, and safety of a single oral dose of SRP-001 (2,000 mg oral suspension) compared to matching placebo in 130 adult participants experiencing moderate-to-severe acute postoperative pain (NPRS ≥ 5 and categorical pain ≥ 2 within 4.5 hours) following extraction of two or more third molars (including at least two bone-impacted mandibular molars). Participants remain in the clinical research unit for 12 hours post-dose for serial efficacy, double-stopwatch onset, safety, and pharmacokinetic assessments, followed by 24-hour rescue diary tracking (two-tiered rescue: ibuprofen 400 mg, then oxycodone 5 mg if needed) and an in-person safety follow-up visit on Day 8 (± 2 days).

研究の種類

介入

入学 (推定)

130

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:CenExel JBR Recruiting

研究場所

    • Utah
      • Salt Lake City、Utah、アメリカ、84107
        • CenExel JBR Clinical Research
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~50年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Is male or female ≥ 18 and ≤ 50 years of age.
  • Requires extraction of 2 or more third molars. At least 2 of the third molars must be a fully or partially bone impacted mandibular molar.
  • Experiences moderate-to-severe pain defined as a score ≥ 2 on the 4-point categorical scale, and a score of ≥ 5 measured by the 0-10 Numeric Pain Rating Scale (NPRS) within 4.5 hours after surgery.
  • Has a body weight ≥ 45 kg and a body mass index (BMI) ≤ 35 kg/m2.
  • Female subjects of child-bearing potential must have used an acceptable method of contraception for at least 30 days prior to randomization and agree to continue use until at least 48 hours post-discharge from the clinic. To be considered not of child-bearing potential, females must be surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal (defined as no menses for 12 months without an alternative medical cause).
  • Free of clinically significant abnormal findings as determined by medical history, physical examination, vital signs, and laboratory tests.
  • Able to provide written informed consent.
  • Is willing and able to comply with study requirements (including diet and smoking restrictions), complete the pain evaluations, remain at the study site for 12 hours post-dose on Day 1, and complete an in-person follow-up visit on Day 8 (± 2 days)

Exclusion Criteria:

  • Known hypersensitivity or allergy to acetaminophen, NSAIDs (including ibuprofen), aspirin, study drug ingredients, anesthetics, or antibiotics.
  • History of active or previous peptic ulceration, gastrointestinal bleeding or perforation, heart failure, renal impairment, uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis; or history or presence of hepatic impairment, or clinically significant baseline laboratory abnormalities at Screening, defined as serum ALT or AST > 1.5× the Upper Limit of Normal (ULN), or total bilirubin > 1.5× ULN (unless attributable to documented Gilbert's syndrome), uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis.
  • Complications from tooth extraction resulting in a "severe" surgical trauma rating.
  • Dental surgery within 60 days prior to Day 1.
  • Positive urine drug screen or alcohol breathalyzer test.
  • Positive pregnancy test (serum at screening, urine pre-surgery on Day 1) or lactating.
  • Known history or suspected (in the opinion of the investigator) of alcoholism or drug abuse within 2 years.
  • Concomitant medications that confound pain assessment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if on a stable dose for ‭≥ 4 weeks prior to Screening.‬‬‬‬‬‬‬‬‬‬‬
  • History of chronic use (defined as daily use for > 2 weeks within 6 months) of NSAIDs, opiates, or glucocorticoids for any condition within 6 months prior to dosing.
  • Difficulty swallowing oral medication.
  • Investigational drug exposure within 30 days or 5 half-lives.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:SRP-001

SRP-001 Single Oral Suspension dose of 2,000 mg

SRP-001 Oral Suspension

プラセボコンパレーター:Matching Placebo for SRP-001

Matching Placebo for SRP-001 Oral Suspension

Matching Placebo for SRP-001 Oral Suspension

他の名前:
  • コントロール

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Sum of Pain Intensity Differences Over 0 to 6 Hours (SPID0-6)
時間枠:0 to 6 hours post-dose

Time-weighted sum of pain intensity differences from baseline over 0 to 6 hours post-dose, assessed using the 0-10 Numeric Pain Rating Scale (NPRS scale 0 -10 higher being worse) comparing SRP-001 (2,000 mg) to placebo.

0 to 6 hours post-dose

二次結果の測定

結果測定
メジャーの説明
時間枠
Time-Weighted Sum of Pain Intensity Differences Over 0 to 2, 0 to 4, and 0 to 8 Hours (SPID0-2, SPID0-4, SPID0-8)
時間枠:0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose

Time-weighted sum of pain intensity differences from baseline over 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose assessed on the 0-10 NPRS (higher being worse)

0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose
Sum of pain relief (TOTPAR)
時間枠:O to 2, 0 to 4, 0 to 6 and 0-8 hours.

Sum of pain relief (TOTPAR) from 0 to 2 (TOTPAR0-2), 0 to 4 (TOTPAR0-4), 0 to 6 hours (TOTPAR0-6), and 0 to 8 (TOTPAR0-8) post dose.

O to 2, 0 to 4, 0 to 6 and 0-8 hours.
Time to a ≥1-Point Reduction in Numeric Pain Rating Scale (T1PMPR)
時間枠:0 to 8 hours post-dose

Time from study drug administration to a ≥1-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments.

0 to 8 hours post-dose
Time to a ≥2-Point Reduction in Numeric Pain Rating Scale (T2PMPR)
時間枠:0 to 8 hours post-dose

Time from study drug administration to a ≥2-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments.

0 to 8 hours post-dose
Time to first use of rescue medication
時間枠:0 - 6, 0-8, 0-24 hours post dose.

Rescue medication time for SRP-001 compared with placebo

0 - 6, 0-8, 0-24 hours post dose.
Total rescue medication consumption
時間枠:0 - 6, 0-8, 0-24 hours post dose.

Total rescue medication consumption for SRP-001 compared with placebo

0 - 6, 0-8, 0-24 hours post dose.
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
時間枠:Day 1 through Follow-up Visit (Day 8 ± 2 days)

Safety as assessed by number of participants with AEs and SAEs for SRP-001 compared with placebo and relationship to study medication

Day 1 through Follow-up Visit (Day 8 ± 2 days)
Pain intensity difference (PID) using the 11-point numeric pain rating scale (NPRS)
時間枠:0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose

Pain intensity difference (PID) Scale is -10 to 10 (higher is better)

0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose
Patient's global evaluation of study drug using a 5 point categorical scale
時間枠:Up to 6 hours post dose

Patient's global evaluation of study drug immediately before the first dose of rescue medication, or at early termination (whichever occurs first) using 5 point scale where 0=poor o 4=excellent

Up to 6 hours post dose
Number of participants with clinically significant abnormalities in laboratory abnormalities
時間枠:Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2

Number of participants with laboratory values judged clinically significant by the investigator in the following panels:

Liver function tests (ALT, AST, bilirubin, alkaline phosphatase) Renal function tests (creatinine, BUN) Hematology parameters (CBC with differential)

Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2
Maximum Observed Plasma Concentration (CMax) of SRP-001
時間枠:Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

CMax of SRP001 following a single 2,000mg oral dose, obtained directly from the plasma concentration data

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Time to maximum observed plasma concentration (Tmax) of SRP-001
時間枠:Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

Tmax of SRP-001 following a single 2,000mg oral dose, obtained directly from the plasma concentration-time data

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Area under the plasma concentration-time curve from 0-12 hours (AUC0-12) of SRP-001
時間枠:Pre-dose through 12 hours post-dose

AUC0-12 of SRP-001 following a single 2,000mg oral dose.

Pre-dose through 12 hours post-dose
Area under the plasma concentration time curve from time 0 to the last measurable concentration (AUC0-t) of SRP-001
時間枠:Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

AUC0-t of SRP001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Area under the plasma concentration time curve from time 0 extrapolated to infinity (AUC0-inf) of SRP-001
時間枠:Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

AUC0-inf of SRP-001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Terminal elimination half life (t 1/2) of SRP-001
時間枠:Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

t 1/2 of SRP-001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Apparent oral clearance (CL/F) of SRP-001
時間枠:Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

CL/F of SRP-001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Apparent volume of distribution during the terminal phase (Vx/F) of SRP-001
時間枠:Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

Vz/F of SRP-001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Pain relief Difference (PR) using the 11-point numeric pain rating scale (NPRS)
時間枠:Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

Pain relief difference (PR)

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

その他の成果指標

結果測定
メジャーの説明
時間枠
Time to first perceptible relief and time to confirmed perceptible pain relief
時間枠:0-4.5 hours post dose

TPPR and TCPR via stopwatch 1

0-4.5 hours post dose
Time to meaningful relief
時間枠:0-4.5 hours post dose

TMPR via Stopwatch 2

0-4.5 hours post dose
Time to complete pain relief
時間枠:0 to 8 hours post-dose

TCOMPR, NPRS = 0

0 to 8 hours post-dose

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Todd M Bertoch, MD、CenExel JBR Clinical Research

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月30日

一次修了 (推定)

2027年2月28日

研究の完了 (推定)

2027年2月28日

試験登録日

最初に提出

2026年11月4日

QC基準を満たした最初の提出物

2026年11月12日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • SRP-001-002

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。